Novel treatment options in stage I non-small-cell lung cancerNovel treatment options in stage I non-small-cell lung cancer
Faculty of Medicine and Health Sciences
Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
Thorax - en vaatheelkunde
Expert review of anticancer therapy
14(2014):9, p. 1007-1020
University of Antwerp
In the last 5 years, the current management of stage I non-small-cell lung cancer has been challenged due to novel surgical approaches and advances in radiation technology. The outcome after a sublobar resection is promising, especially for tumors less than 2 cm. Other treatment opportunities are available for high risk patients with comorbidity and impaired pulmonary function. Stereotactic ablative body radiotherapy is a good alternative treatment to surgery, especially in elderly and comorbid patients. However, randomized evidence comparing sublobar resection and stereotactic radiotherapy is presently lacking. The most recent development in radiotherapy is hadron therapy with a presumed reduced toxicity because of its peculiar physical and biological effects. Promising thermal and microwave ablative techniques are in development and have specific niche indications.